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Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although
photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large
randomizedclinicaltrials(RCTs),somepatientswithDMEcontinuetolosevisiondespitetreatment.PharmacotherapiesforDME
include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.
1.Introduction
Diabetic macular edema (DME) is one of the most common
causes of visual loss in patients with diabetes mellitus [1].
The pathophysiology of DME involves dilated capillaries,
retinal microaneurysms, and loss of pericytes, with eventual
impairment of the blood-retinal barrier (BRB) [2]. Break-
downoftheBRBresultsinﬂuidleakageintotheextracellular
space, which disrupts macular structure and function on a
cellular level [3, 4]. A technique for visualizing molecules
leaked through the outer BRB in a diabetic rodent model
has recently been described, which should increase our
understanding of this process [5].
This leakage may be analyzed in terms of physical forces
[6]. Starling’s Law states that the net ﬂow of ﬂuid across
a vessel wall is increased by hydrostatic pressure within
the lumen of the vessel and decreased by oncotic pressure
within the lumen. In diabetic patients, hydrostatic pressure
may be increased because of systemic hypertension and
retinal ischemia, increasing the likelihood of exudation.
This problem is exacerbated because increased hydrostatic
pressure may lead to dilatation and tortuosity of retinal
arterioles, capillaries, and venules, which increases vessel
wall tension and further disruption of the BRB according to
LaPlace’s Law [7]. Other factors may also contribute to this
edema, such as osmotic stress leading to Muller cell swelling,
such as that reported with retinal detachment [8].
The pathogenesis of DME is at this time poorly deﬁned,
but is believed to involve angiogenesis, inﬂammation, and
oxidative stress [9]. Hyperglycemia is reported to lead to
capillary endothelial damage and alterations in leukocyte
function [10]. In addition, hyperglycemia has been reported
to activate oxidative stress agents, such as advanced glycation
endproducts and the protein kinase C (PKC) pathway [11].
Various inﬂammatory mediators appear to play a role in
promoting DME, including vascular endothelial growth
factor (VEGF) [12], placental growth factor (PlGF) [13], and
hepatocyte growth factor (HGF) [14].
TheWisconsinEpidemiologicStudyofDiabeticRetinop-
athy (WESDR) reported that approximately 14% of patients
with type 2 diabetes developed DME over a 10-year period
[15]. More recently, the 10-year incidence of DME in a
Spanish population of patients with type 1 diabetes was
reported as approximately 11% [16]. Reported risk factors
for diabetic retinopathy and DME include duration of dia-
betes, as well as the severity of hyperglycemia, hypertension,
and hyperlipidemia [17].
Intensive control of systemic factors, including blood
sugar, blood pressure, and serum lipids, has been reported to
reduce complications of diabetic retinopathy in patients with2 Experimental Diabetes Research
Table 1: Selected clinical trials of corticosteroids in treatment of
diabetic macular edema.
Agent (no. patients) Main outcomes Reference
Intravitreal
triamcinolone (693)
Less favorable outcomes
versus photocoagulation
at 24 and 36 months
[22, 23]
Peribulbar
triamcinolone (109)
Less favorable outcomes
versus intravitreal
triamcinolone at 34 weeks
[28]
Fluocinolone acetonide
implant (Retisert) (197)
Eﬀective treatment of
DME at 36 months, but
high risks of cataract and
glaucoma
[32]
Fluocinolone acetonide
implant (Iluvien) (956)
Generally favorable results
at 24 months [34]
Dexamethasone drug
delivery system
(Ozurdex) (171)
Generally favorable results
at 90 days [36]
type 1 [18]a n dt y p e2[ 19] diabetes. Macular photocoagula-
tionwasdemonstratedasatreatmentforclinicallysigniﬁcant
macular edema (CSME) by the Early Treatment Diabetic
Retinopathy Study (ETDRS) in 1985 [20]. Newer clinical
trials using intravitreal pharmacotherapies have reported
many favorable outcomes. The current paper will review the
literature and various randomized clinical trials (RCTs) on
emerging pharmacotherapies for the treatment of DME.
2. Ocular Agents
2.1. Corticosteroids. Corticosteroids may have multiple
mechanisms of action in the treatment of DME. In addition
to their anti-inﬂammatory properties, corticosteroids have
been reported to reduce the activity of VEGF [21]. Intrav-
itreal triamcinolone acetonide (IVTA) has been reported for
the treatment of DME (Figure 1)( Table 1). Currently, there
are at least four preparations reported in clinical studies:
Kenalog-40 (Bristol-Myers Squibb, Princeton, NJ, USA);
preservative-free triamcinolone acetonide from compound-
ing pharmacies; Triesence (Alcon, Fort Worth, TX, US); and
Trivaris (Allergan, Irvine, CA, USA).
The Diabetic Retinopathy Clinical Research Network
(DRCR) protocol B compared two doses (1 and 4mg) of
IVTA versus photocoagulation for DME [22]. For most
patients, photocoagulation produced more favorable out-
comes than did IVTA at 24 months of followup. Similar
results were reported at 3-year followup [23]. The most
common complications of IVTA are cataract formation [24]
and increased intraocular pressure (IOP) [25]. Pseudoen-
dophthalmitis [26] and infectious endophthalmitis occur
much less commonly. The rate of infectious endophthalmitis
after IVTA is low in reported series. For example, in an
analysis of two large RCTs (from the DRCR network and
the Standard Care Versus Corticosteroid for Retinal Vein
Occlusion (SCORE) trials), the rate of endophthalmitis after
IVTA was 0.05% [27].
A triamcinolone-eluting intravitreal implant (I-vation,
SurModics, Inc., MN, USA) for the treatment of DME
was suspended in a phase 2b RCT after the publication
of the DRCR network results showing a beneﬁt of laser
photocoagulation over IVTA in treatment of DME [22].
In order to reduce the risk of complications associ-
ated with IVTA, the use of peribulbar triamcinolone was
investigated. In a single-center, prospective trial, peribulbar
triamcinolone demonstrated lesser eﬃcacy than did IVTA
[28]. The DRCR reported that peribulbar triamcinolone did
not signiﬁcantly beneﬁt patients with mild DME and visual
acuity of 20/40 or better [29].
To reduce the need for repeated intravitreal injec-
tions, several extended-release corticosteroid delivery sys-
tems have been studied. A ﬂuocinolone-acetonide- (FA-)
eluting intravitreal implant (Retisert, Bausch and Lomb,
NY, USA) has received FDA approval for the treatment of
chronic, noninfectious posterior segment uveitis [30]. This
is a nonbiodegradable device that releases 0.59μg/day of FA
into the vitreous cavity. It must be implanted in an operating
room or similar setting. In an RCT, the eﬀects of the device
versus photocoagulation for DME were studied. At one
year, DME was resolved by clinical examination and optical
coherence tomography (OCT) in 57% of patients with the
FA implant versus 20% of patients with photocoagulation.
There were no statistically signiﬁcant diﬀerences in ﬁnal
visual acuity between the two groups [31]. At 3 years,
patients randomized to receive the FA implant had persistent
treatment of macular edema, but 95% of phakic eyes
developed signiﬁcant cataract, and about one-third of eyes
had IOP above 30mm Hg [32].
A smaller ﬂuocinolone acetonide-eluting device (Ilu-
vien, Alimera Sciences, Alpharetta, GA, USA) may be
administered through a 25-gauge device in a clinic set-
ting. The Famous (Pharmacokinetic and Eﬃciency Study
of Fluocinolone Acetonide Inserts in Patients with DME)
study compared 0.2 versus 0.5μg/day ﬂuocinolone injection
devices in patients with persistent DME despite at least one
previous focal/grid laser therapy [33]. There was a mean
improvement of 5 letters in visual acuity in both groups at 3-
month followup. The number of patients in the trial was too
small to determine whether there were clinically meaningful
diﬀerences in results obtained from the two doses.
TheFluocinoloneAcetonideforMacularEdema(FAME)
study comprised 2 phase 3 RCTs assessing the eﬃcacy and
safety of 0.2μg/day (low dose) and 0.5μg/day (high dose)
inserts in patients with DME with persistent edema despite
at least one macular laser treatment [34]. The primary study
endpoint was deﬁned as improvement in visual acuity by
15 or more letters at 2 years. At 24 months, the primary
endpointwasachievedin28.7%and28.6%oflow-andhigh-
dose insert groups compared with 16.2% in the sham group.
Elevated intraocular pressure requiring incisional surgery
occurred in 3.7%, 7.6%, and 0.5% of the low-dose, high-
dose, and sham groups, respectively.
The dexamethasone drug delivery system (DDS) [Ozur-
dex, Allergan, Irvine, California] is a biodegradable,
sustained-release device approved by the US FDA for the
treatment of macular edema associated with retinal vein
occlusion and noninfectious posterior segment uveitis. A
phase 2 RCT in patients with persistent macular edemaExperimental Diabetes Research 3
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Figure 1: (a) Fundus photograph, left eye, of a patient with persistent diabetic macular edema following focal/grid photocoagulation.
(b) Early phase ﬂuorescein angiograph, left eye, demonstrating abnormal hyperﬂuorescence in the macula. (c) Late phase ﬂuorescein
angiograph, left eye, demonstrating profuse leakage consistent with angiographic macular edema. (d) Spectral domain optical coherence
tomograph, left eye, demonstrating cystoid macular edema. (e) Following treatment with intravitreal triamcinolone acetonide, 4mg in
0.1mL, spectral domain optical coherence tomography demonstrates marked improvement in cystoid macular edema.
secondary to various etiologies, including DME, showed
that the dexamethasone DDS produced improvements in
visual acuity, macular thickness, and ﬂuorescein leakage
that were sustained for up to 6 months [35]. In an RCT,
the safety and eﬃcacy of the dexamethasone DDS in the
treatment of DME was studied [36]. Patients with persistent
macular edema (at least 90-day duration) were randomized
to treatment with 700μg or 350μg of dexamethasone DDS
or observation. At 3 months, visual acuity improved by
10 letters or more in 30% of eyes in the 700μgg r o u p ,
20% of eyes in the 350μg group, and 12% of eyes in the
observation group. A more recent study reported that the
dexamethasone DDS improved visual acuity and macular
edema in previously vitrectomized eyes with diﬀuse DME
[37].
2.2. Vascular Endothelial Growth Factor Antagonists. VEGF
appears to play an important role in the pathogenesis of
diabetic retinopathy [38]. In animal models, injection of
VEGF causes breakdown of the BRB [39], and elevated levels
of VEGF cause macular edema [40]. An oral nonselective
b l o c k e ro fV E G Fr e c e p t o rw a sf o u n dt or e d u c eD M E ,
suggesting that VEGF antagonists may provide beneﬁt in
treatment of DME [41]. Four intravitreal anti-VEGF agents
are currently available commercially, although none is FDA-
approved for the treatment of DME (Table 2).
2.2.1. Pegaptanib. Pegaptanib (Macugen, Eyetech Pharma-
ceuticals, Palm Beach Gardens, FL, USA) is a pegylated
aptamer that targets the VEGF165 isoform. Pegaptanib is
approved by the FDA for the treatment of neovascularExperimental Diabetes Research 5
Table 2: Selected clinical trials of VEGF antagonists in treatment of
diabetic macular edema.
Agent (no. patients) Main outcomes Reference
Pegaptanib (260)
More favorable
outcomes versus sham at
2 years
[43]
Bevacizumab
DRCR phase II (121)
More favorable
outcomes versus
photocoagulation at 3
weeks
[45]
BOLT study (80)
More favorable
outcomes versus
photocoagulation at 1
year
[46]
Ranibizumab
READ-2 study (126)
More favorable
outcomes versus
photocoagulation at 2
years
[53]
DRCR protocol I (691)
Ranibizumab with
photocoagulation more
favorable than
photocoagulation alone
at 2 years
[54]
RESTORE study (345)
Ranibizumab with or
without
photocoagulation more
favorable than
photocoagulation alone
at 1 year
[57]
RISE/RIDE studies (377)
More favorable
outcomes versus sham at
2 years
[59]
RESOLVE study (151)
More favorable
outcomes versus sham at
1 year
[60]
Aﬂibercept
DA VINCI study (219)
More favorable
outcomes versus
photocoagulation at 1
year
[66]
age-related macular degeneration (AMD) and was the ﬁrst
anti-VEGF medication reported to have eﬃcacy in the
treatment of DME. The Macugen Diabetic Retinopathy
Study Group conducted a phase 2 RCT of pegaptanib for
fovea-involving DME [42] .A f t e r3 6w e e k so ff o l l o w u p ,
the pegaptanib-treated eyes had better visual acuity, more
reduction in central retinal thickness, and less need for
laser photocoagulation compared to the sham group. More
recently, a phase 2/3 RCT reported that pegaptanib therapy
was associated with improved visual outcomes in patients
with DME for up to 2 years [43].
2.2.2. Bevacizumab. Bevacizumab (Avastin, Genentech, Inc.,
South San Francisco, CA, US) is a full-length recombi-
nant humanized antibody against all isoforms of VEGF-
A. Bevacizumab is approved by the FDA for the systemic
treatment of metastatic colorectal cancer, metastatic breast
cancer, and nonsmall cell lung cancer [44]. The agent is used
commonly as an oﬀ-label intravitreal injection (Figure 2).
The DRCR network conducted a randomized study of 121
eyes with DME over a 12-week period [45]. There were
ﬁve treatment arms: focal photocoagulation, 2 consecu-
tive 1.25mg bevacizumab injections, 2 consecutive 2.5mg
bevacizumab injections, 1.25mg bevacizumab followed by
sham injection, and combination of photocoagulation with
2 consecutive 1.25mg bevacizumab injections. The groups
that received two bevacizumab injections without laser had
a signiﬁcant improvement in visual acuity over the laser-
only group. There were no detectable diﬀerences between the
1.25mg and 2.5mg doses. The single injection group had
no advantage over the laser-only group. The combination of
laser and bevacizumab had comparable results to the laser-
only group with a trend toward worse short-term vision than
eyes that received two bevacizumab injections. The DRCR
is currently planning an RCT to compare bevacizumab to
ranibizumab in the treatment of DME.
In the BOLT (Bevacizumab Or Laser Therapy in the
Management of DME) study, repeated intravitreal beva-
cizumab injections were compared with modiﬁed ETDRS
photocoagulation in patients with persistent DME. A total
of 80 patients with center-involving DME and at least
one prior photocoagulation without evidence of advanced
macular ischemia were included. Patients were randomized
to 2 arms: intravitreal bevacizumab (injections at baseline,
6- and 12-week followup with subsequent injections every
6 weeks based on OCT-guided retreatment protocol) or
photocoagulation (at baseline with subsequent retreatment
every 4 months if clinically indicated by ETDRS guidelines).
At 12 months, bevacizumab had a greater treatment eﬀect
than did photocoagulation. The bevacizumab arm gained a
median of 8 ETDRS letters, whereas the photocoagulation
group lost a median of 0.5 ETDRS letters. Approximately
31% of patients in the bevacizumab arm versus 7.9%
of patients in the laser arm gained ≥10 ETDRS letters
(P = 0.01). The decrease in central macular thickness was
signiﬁcantly more in the bevacizumab group compared to
the photocoagulation group [46]. There was no progression
of macular ischemia in either treatment group [47].
2.2.3. Ranibizumab. Ranibizumab (Lucentis, Genentech,
Inc. South San Francisco, CA, USA) is a recombinant
humanized monoclonal antibody fragment that binds all
isoformsofVEGF-Awithhighaﬃnity.RanibizumabisFDA-
approved for the treatment of neovascular AMD and retinal
vascular occlusion [48–51]. The Ranibizumab for Edema of
the Macula in Diabetes (READ-2) study randomized 126
eyes with DME to 3 groups: ranibizumab only (injection
at baseline, months 1, 3, and 5); photocoagulation (at
baseline and at 3 months if needed); combined ranibizumab
and photocoagulation (photocoagulation and ranibizumab
at baseline, and ranibizumab at 3 months if needed)
[52]. Patients randomized to ranibizumab only showed a
signiﬁcantly better visual outcome at 6 months compared
with the other 2 groups. For patients with data available at 6
months, improvement of 3 lines or more in vision occurred6 Experimental Diabetes Research
Figure 2: (a) Fundus photograph, right eye, of a patient with persistent diabetic macular edema following focal/grid photocoagulation. (b)
Spectral domain optical coherence tomograph, right eye, demonstrates cystoid macular edema and subretinal ﬂuid. (c) Following additional
focal/grid photocoagulation and treatment with intravitreal bevacizumab, 1.25mg in 0.1mL, fundus photography demonstrates marked
improvement in diabetic macular edema. (d) Follow-up spectral domain optical coherence tomography demonstrates marked improvement
in intraretinal and subretinal ﬂuid.
in 22% of patients in the ranibizumab-only arm, none in the
photocoagulation-only arm, and 8% in combined arm. At
24 months, the study reported that intravitreal ranibizumab
provided persistent treatment beneﬁts [53].
DRCR protocol I evaluated ranibizumab and IVTA
in combination with photocoagulation by randomizing
patients into four arms: ranibizumab with prompt (within
one week) photocoagulation, IVTA with prompt photoco-
agulation, sham injection with prompt photocoagulation,
and ranibizumab with photocoagulation deferred for at
least 24 weeks [54]. The treatment protocol included a
baseline treatment followed by intravitreal study medication
or sham injection retreatments every 4 weeks through the
12-week visit. After the 16-week visit, retreatment wasExperimental Diabetes Research 7
at the investigator’s discretion according to web-based
predetermined criteria. Ranibizumab with prompt or
deferred photocoagulation resulted in more favorable visual
acuity and central macular thickness outcomes compared
with photocoagulation alone at 1 and 2 years of followup. In
ranibizumab-treated eyes, the results were similar whether
photocoagulation was given with the ﬁrst injection or
deferred for at least 24 weeks. IVTA combined with photoco-
agulation did not result in better visual outcomes compared
with photocoagulation alone. In pseudophakic eyes, the
IVTA with prompt photocoagulation group had similar
visual outcomes to the 2 ranibizumab groups, suggesting
that cataract formation may have aﬀected the visual acuity
outcomes in phakic eyes treated with IVTA. Two-year visual
outcomes were similar to 1-year results and reinforced
the conclusion that ranibizumab with prompt or deferred
photocoagulation should be considered for patients with
vision impairment of worse than 20/32 secondary to DME
[55]. This study utilized a web-based algorithm to determine
treatment decisions; in clinical practice, this may not be
feasible, but the general approach may be emulated [56].
The RESTORE phase 3 study reported that ranibizumab
monotherapy or combined with laser photocoagulation
provided superior visual acuity gain over standard photo-
coagulation in the treatment of DME [57]. The one-year
resultsshowedthat37%ofpatientstreatedwithranibizumab
0.5mg alone, and 43% of those treated with ranibizumab
plus laser therapy, gained vision improvement of 10 letters
or more compared to 16% of patients treated with laser
alone. At one year, no diﬀerence was detected between the
ranibizumab and ranibizumab plus laser arms.
A recent study showed that the addition of one IVTA
injection or two ranibizumab injections to eyes receiving
focal laser treatment for DME and panretinal photocoagu-
lation is associated with signiﬁcantly better visual acuity and
decreased macular edema by 14 weeks [58]. However, these
improvements were not maintained when study subjects
were followed for 56 weeks for safety outcomes.
Two additional phase 3 RCTs (RISE and RIDE) were
conducted to evaluate the eﬃcacy, durability, and long-term
safety of monthly ranibizumab injections in patients with
center-involving DME. The primary eﬃcacy outcome was
theproportionofsubjectswhogainedmorethan15lettersin
visual acuity compared with baseline at 24 months. Patients
were randomized 1:1:1 to receive monthly injections of
0.3mg ranibizumab, 0.5mg ranibizumab, or sham. These
studies were not designed to compare the two doses of
ranibizumab, but each dose against the sham injection. At
24 months, RISE met its primary endpoint with statistically
signiﬁcant improvements in vision in ranibizumab-treated
patients compared to sham injections [59].
The safety and eﬃcacy of 2 concentrations of intravitreal
ranibizumab in the treatment of DME were compared in
the RESOLVE phase 2 trial [60]. Subjects were randomized
to receive 3 monthly injections with either 0.3 or 0.5mg
ranibizumab or placebo. Treatment was then administered
on an as-needed basis, depending on the response to initial
treatment. If edema persisted, then the dose of ranibizum-
ab was doubled after 1 month. Photocoagulation after 3
injections was given if needed. When the pooled data from
thedouble-doseranibizumabgroup(n = 77)werecompared
with the sham group (n = 32), there were statistically signifi-
cant improvements in vision and central macular thickness.
In contrast to intravitreal corticosteroids, cataract pro-
gression associated with intravitreal VEGF antagonists has
not been identiﬁed. Some patients do sustain IOP elevation
following repeated injections of VEGF antagonists [61], but
this eﬀect does not appear to be as strong as that associated
withintravitrealcorticosteroids.Inmostpublishedseries,the
rate of endophthalmitis following treatment with intravitreal
anti-VEGF injections is about 0.03% per injection [62–64].
The incidence and severity of systemic and ocular adverse
eventsthatareassociatedwithrepeatedintravitrealinjections
of two doses of ranibizumab (0.5mg versus 2.0mg) in
subjects with DME are being investigated in READ-3 study.
2.2.4. Aﬂibercept. Aﬂibercept, or VEGF trap-eye, (Eylea,
Regeneron, Tarrytown, NY, USA), is a recombinant fusion
protein with activity against all VEGF-A isoforms and PlGF
that is FDA-approved for the treatment of neovascular AMD
and has been shown to have short-term eﬃcacy in the
treatment of DME [65]. The DA-VINCI study assessed the
eﬃcacy and safety of intravitreal aﬂibercept versus laser
photocoagulation in the treatment of DME. Patients were
randomized to one of the following treatment arms: 0.5mg
aﬂibercept every 4 weeks, 2mg aﬂibercept every 4 weeks,
2mg aﬂibercept every 8 weeks, 2mg aﬂibercept as needed,
or photocoagulation. At 24 weeks, the mean change in
BCVA for aﬂibercept arms ranged from +8.5 to +11.4
letters compared to the mean change of +2.5 letters in
the laser-treated eyes (P<0.01). There was no statistical
signiﬁcantdiﬀerencebetweentheaﬂiberceptarms.Anatomic
eﬀects (mean change in central retinal thickness) ranged
from −127μmt o−195μmi na ﬂ i b e r c e p ta r m sc o m p a r e d
to −68μm in laser-treated eyes at 24 weeks (P<0.01).
At 52 weeks, the mean change in BCVA for aﬂibercept
arms ranged from +9.7 to +13.1 letters compared to the
mean change of −1.3 letters in the laser-treated eyes (P<
0.01) [66]. In this study population, intravitreal aﬂibercept
produced signiﬁcant improvements in visual acuity and
retinal thickness as compared to laser photocoagulation at
both 24 and 52 weeks. At this time, aﬂibercept is not
approved by the US FDA for the treatment of DME.
2.3. Vitreolysis. The vitreous has been implicated as a
cause of DME by several mechanical and physiological
mechanisms, including macular traction and concentration
ofvasopermeablefactorsinthemacularregion[67].Arecent
prospective trial by DRCR network evaluated visual and
anatomical outcomes of pars plana vitrectomy (PPV) with-
outconcomitantcataractsurgeryforDMEineyeswithmod-
erate vision loss and vitreomacular traction. Retinal thicken-
ing was improved in most eyes, but visual acuity results were
less consistent with improvement of ≥10 letters in 38%, and
worsening by ≥10 letters in 22% at 6 months [68]. In a sub-
sequent analysis, the DRCR reported that better visual out-
comes were associated with worse baseline visual acuity and
in eyes in which an epiretinal membrane was removed [69].8 Experimental Diabetes Research
Table 3: Selected Other Ocular Agents in Treatment of Diabetic
Macular Edema.
Agent (# patients) Main Outcomes Reference
Celecoxib (86)
Unfavorable outcomes
versus photocoagulation at
2 years
[81]
Nepafenac (1) Some evidence of eﬃcacy
in case report [83]
Etanercept (7) Some evidence of eﬃcacy
in pilot study [85]
Inﬂiximab (4) Some evidence of eﬃcacy
in pilot study [87]
Mecamylamine (23) Some evidence of eﬃcacy
in pilot study [90]
Enzymatic vitreolysis with or without PPV has been
studied in the treatment of DME. Intravitreal hyaluronidase
(Vitrase, ISTA Pharmaceuticals, Irvine, CA, USA) has shown
evidence of safety and eﬃcacy in reducing vitreous hemor-
rhage secondary to diﬀerent etiologies, including prolifera-
tive diabetic retinopathy (PDR), although it has not received
FDA approval for this indication [70, 71].
Inductionofaposteriorvitreousdetachment(PVD)may
be beneﬁcial in the treatment of DME [72]. Enzymes that
may have eﬃcacy in creating a PVD include hyaluronidase,
plasmin, chondroitinase, and dispase [73]. Autologous plas-
min has been used by itself or as adjunct to PPV in the
treatment of DME [74, 75]. Microplasmin is a recombinant
human protein derived from the yeast Pichiapastoris.I ti sa
truncated form of the human protein plasmin with intact
protease activity. The Microplasmin Intravitreous Injection
(MIVI) trial was a phase 2 RCT that evaluated the safety
and eﬃcacy of intravitreal microplasmin in facilitating the
creation of a total PVD in patients scheduled for PPV [76].
The study showed that microplasmin injection at a dose of
125μg led to a greater likelihood of induction of PVD than
placebo. Patients receiving microplasmin were signiﬁcantly
more likely to have resolution of vitreomacular traction and
not to require PPV.
2.4. Other Ocular Agents. Other ocular agents have been
studied as treatments for DME (Table 3). Animal models
have demonstrated an important role for inﬂammation in
diabeticretinopathy[77].Inearlystagesofdiabeticretinopa-
thy, there is upregulation of cyclo-oxygenase-2 (COX-2) that
leads to elevated prostaglandin production and increased
expression of VEGF with increased risk of vascular leakage
and retinal neovascularization [78]. High doses of aspirin
and intermediate doses of COX-2 inhibitors (celecoxib)
have shown to be beneﬁcial in early stages of experimental
diabetic retinopathy [79]. Periocular celecoxib-containing
microparticles have shown to inhibit elevation of VEGF
f o ra sl o n ga s6 0d a y si na n i m a lm o d e l s[ 80]. A recent
multicenter clinical trial failed to show any visual function
beneﬁts with celecoxib treatment in DME, although, there
was a suggestive eﬀect of celecoxib in reducing ﬂuorescein
leakage [81].
Table 4:SelectedSystemicAgentsinTreatmentofDiabeticMacular
Edema.
Agent (# patients) Main Outcomes Reference
Ruboxistaurin (686) Did not meet primary outcome
measure at 30 months [102]
Fenoﬁbrate (9795) Favorable outcomes versus
placebo at average of 5 years [104]
Rosiglitazone (30)
Some evidence of eﬃcacy at 3
months, but also may worsen
DME in some patients
[107]
Nepafenac (Nevanac, Alcon, Ft. Worth, TX, USA), an
FDA-approved topical nonsteroidal anti-inﬂammatory drug
(NSAID), is a prodrug that is converted to amfenac in the
anterior chamber [82]. In a pilot study, nepafenac has shown
some eﬃcacy in the treatment of DME [83]. The DRCR is
currentlybeginningaphase2RCTstudyingtheuseoftopical
nepafenac to treat nonclinically signiﬁcant DME.
Etanercept (Enbrel, Amgen, Inc. Thousand Oaks, CA,
USA and Wyeth, Madison, NJ, USA), a recombinant fusion
protein with activity against TNF-α, is FDA-approved for the
treatment of psoriatic disease [84]. Intravitreal etanercept
has shown some evidence of eﬃcacy against refractory DME
[85].
Inﬂiximab (Remicade, Centocor, Horsham, PA, USA)
is another TNF-α antagonist that is FDA-approved for the
treatment of Crohn’s disease [86]. A pilot study showed
beneﬁts from systemic inﬂiximab in treatment of DME [87].
A pilot study of intravitreal inﬂiximab is continuing.
Stimulation of nicotinic acetylcholine (nACh) receptors
on vascular endothelial cells promotes angiogenesis and
vascular permeability in animal models [88, 89]. A recent
multicenter phase 1/2 clinical trial evaluated the safety and
bioactivity of topical mecamylamine, an antagonist of nACh
receptors, in patients with DME [90]. Mecamylamine drops
were well tolerated. The study suggested that administration
of topical mecamylamine may have heterogeneous eﬀects
in patients with DME. The heterogeneous response may be
secondary to variable expression of nACh receptor subtypes
on endothelial cells.
A pilot study has reported a short-term positive response
to intravitreal erythropoietin in a group of patients with
chronic DME unresponsive to other therapies [91].
3. Systemic Agents
Various systemic agents have been studied in the treatment
of DME (Table 4). Activation of protein kinase C (PKC) may
play an important role in the development and progression
of diabetic retinopathy [92–98]. Ruboxistaurin (Arxxant, Eli
Lilly and Company, Indianapolis, IN, USA) is a selective
antagonist of PKC βIa n dP K CβII [99]. The PKC-Diabetic
Retinopathy Study (PKC-DRS) reported that ruboxistaurin
was associated with a reduced incidence of moderate visual
loss (doubling of the visual angle) [100]. The PKC-DRS 2
reported that ruboxistaurin was associated with a reduced
incidence of sustained moderate visual loss (for 6 months)Experimental Diabetes Research 9
[101]. The PKC-DME Study (PKC-DMES) reported some
evidence that ruboxistaurin was associated with reduced
progressionofDME,althoughthiswasasecondaryendpoint
[102].RuboxistaurinhasnotreceivedapprovalfromtheUSA
FDA.
Fenoﬁbrate is a ﬁbric acid derivative with pleiotropic
eﬀects that is used as a lipid-modifying agent [103]. The
fenoﬁbrate intervention and event lowering in diabetes
(FIELD) study, a large RCT, showed that treatment with
fenoﬁbrate reduces the need for laser treatment in patients
with PDR and DME [104].
Rosiglitazone (Avandia, GlaxoSmith Klein, Research Tri-
angle Park, NC, US) is a peroxisome proliferator-activated γ
ligand that is used in the treatment of type 2 diabetes [105].
Treatment with rosiglitazone has been shown to reduce the
rate of progression to PDR [106], however, in some patients,
it may be associated with increased risk of DME [107].
4. Summary Statement
For decades, standard treatments for DME have included
tighter control of systemic metabolic factors, as well as
photocoagulation. However, some patients continue to lose
vision despite these therapies, which has led to the inves-
tigation of various pharmacotherapies for DME. At this
time, both intravitreal corticosteroids and intravitreal anti-
VEGF agents are widely used in clinical settings. The role
of combination therapies (both various medications with
each other as well as medications with photocoagulation) is
yet to be determined. As we continue to collect data from
current and future RCTs, management strategies for DME
will continue to evolve.
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